Peter Socrates Creticos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Socrates Creticos has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Amarjot Kaur
Merck & Co., Inc., Whitehouse Station, NJ USA
2 shared publications - Harold Kim
Department of Medicine, McMaster University, Hamilton, Canada
2 shared publications - Harold S. Nelson
National Jewish Health, Denver, Colo
2 shared publications Hendrik Nolte
ALK, Bedminster, NJ; ALK, Horsholm, Denmark
2 shared publications- Hendrik Nolte
Merck & Co, Kenilworth, NJ
2 shared publications - Jacques Hébert
Centre de Recherche Appliquée en Allergie de Québec, Québec, Canada
2 shared publications
Latest Publications
- Top Cited Papers
- 27 April 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (6) , 1415-1427
Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma
- 27 April 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (6) , 1415-1427
Top Cited PapersAllergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma
- 1 July 2022
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 43 (4) , 260-266
Subcutaneous allergen immunotherapy in the treatment of allergic respiratory disease
Subcutaneous immunotherapy is recognized as a cornerstone in the management of allergic respiratory disease in patients who are properly characterized with allergy and with allergic rhinoconjunctivis and/or well-controlled asthma, and who are willing to adhere to the rigorous treatment program. A key tenet is that it affords the opportunity to effect long-term clinical remission through its disease-modifying properties. Furthermore, it has the potential to prevent the progression of allergic rhinitis to asthma, prevent new allergen sensitivities, and improve a patient's quality of life.
- 1 July 2022
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 43 (4) , 260-266
Subcutaneous allergen immunotherapy in the treatment of allergic respiratory disease
Subcutaneous immunotherapy is recognized as a cornerstone in the management of allergic respiratory disease in patients who are properly characterized with allergy and with allergic rhinoconjunctivis and/or well-controlled asthma, and who are willing to adhere to the rigorous treatment program. A key tenet is that it affords the opportunity to effect long-term clinical remission through its disease-modifying properties. Furthermore, it has the potential to prevent the progression of allergic rhinitis to asthma, prevent new allergen sensitivities, and improve a patient's quality of life.
- 7 September 2021
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 21 (6) , 602-610
New insights in mite immunotherapy – sublingual tablets
Purpose of review: Sublingual tablet immunotherapy has been demonstrated to be effective for allergies induced by exposure to grass, ragweed, specific trees (Japanese Cedar; birch homologous tree mix), and house dust mites (HDM). This review provides both an overview of the evidence-based clinical studies that address the use of the HDM SLIT-tablet for the treatment of HDM-induced allergic rhinitis/conjunctivitis and its appropriate use in carefully selected asthmatic patients and provides the clinician with practical management considerations. Recent findings: Solid evidence-based clinical studies have shown that the HDM SLIT-tablet is both well tolerated in patients with mild-to-moderate asthma and has demonstrated a meaningful improvement in exacerbations, need for rescue medication, quality of life, and asthma control. Summary: The HDM SLIT-tablet provides the allergy specialist with a well-tolerated treatment that has established superior safety to subcutaneous injection therapy, which can be administered easily as a sublingual dissolvable tablet, and which provides the opportunity to address one of the more difficult aspects in the management of an inducer of perennial allergic disease – that of persistent airway inflammation and allergic asthma.
- 7 September 2021
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 21 (6) , 602-610
New insights in mite immunotherapy – sublingual tablets
Purpose of review: Sublingual tablet immunotherapy has been demonstrated to be effective for allergies induced by exposure to grass, ragweed, specific trees (Japanese Cedar; birch homologous tree mix), and house dust mites (HDM). This review provides both an overview of the evidence-based clinical studies that address the use of the HDM SLIT-tablet for the treatment of HDM-induced allergic rhinitis/conjunctivitis and its appropriate use in carefully selected asthmatic patients and provides the clinician with practical management considerations. Recent findings: Solid evidence-based clinical studies have shown that the HDM SLIT-tablet is both well tolerated in patients with mild-to-moderate asthma and has demonstrated a meaningful improvement in exacerbations, need for rescue medication, quality of life, and asthma control. Summary: The HDM SLIT-tablet provides the allergy specialist with a well-tolerated treatment that has established superior safety to subcutaneous injection therapy, which can be administered easily as a sublingual dissolvable tablet, and which provides the opportunity to address one of the more difficult aspects in the management of an inducer of perennial allergic disease – that of persistent airway inflammation and allergic asthma.
- 10 April 2018
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (7) , 605-616
Ragweed Sublingual Tablet Immunotherapy: Part I – Evidence-Based Clinical Efficacy and Safety
Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.
- 10 April 2018
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (7) , 605-616
Ragweed Sublingual Tablet Immunotherapy: Part I – Evidence-Based Clinical Efficacy and Safety
Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.
- 1 February 2016
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 36 (1) , 103-124
Allergen Immunotherapy
- 1 February 2016
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 36 (1) , 103-124
Allergen Immunotherapy
- Open Access
- 10 November 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 55
Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.
- 10 November 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 55
Open AccessEfficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.
- Open Access
- 30 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 53
The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children
The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.
- 30 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 53
Open AccessThe efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children
The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.
- 1 March 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 133 (3) , 751-758
Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis
- 1 March 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 133 (3) , 751-758
Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis
- Open Access
- 1 January 2014
- Published by Elsevier in World Allergy Organization Journal
- Vol. 7 (1) , 1-30
Advances in synthetic peptide immuno-regulatory epitopes
- 1 January 2014
- Published by Elsevier in World Allergy Organization Journal
- Vol. 7 (1) , 1-30
Open AccessAdvances in synthetic peptide immuno-regulatory epitopes